Learn More About the PROSERA Study
Now enrolling: The PROSERA phase 3 study of seralutinib in adults with pulmonary arterial hypertension.
Seralutinib for the Treatment of Pulmonary Arterial Hypertension: Results from the Phase 2 TORREY Study (Plain Language Summary)